Table Graph
      published meta-analysis   sensitivity analysis   studies

casirivimab/imdevimab (Ronapreve) in COVID-19 (hospitalized or not) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalization or deathdetailed resultsWei, 2022 0.39 [0.26; 0.59] 0.39[0.26; 0.59]Wei, 202210%NAnot evaluable hospitalizationdetailed resultsWei, 2022 0.39 [0.30; 0.51] 0.39[0.30; 0.51]Wei, 202210%NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-13 07:18 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 87 - treatments: 771 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons